Navigation Links
Peregrine Pharmaceuticals Appoints Dr. Marvin R. Garovoy as Head of Clinical Science
Date:1/11/2010

op15='81131652';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.peregrineinc.com/">www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended October 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release


    Contacts:
    GendeLLindheim BioCom Partners
    Investors       
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results
2. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial
3. Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
4. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
5. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
8. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
9. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
10. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
11. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... N.J., Jan. 28 Arno Therapeutics, Inc., a,privately ... entered into,worldwide, exclusive license agreements with The Ohio ... novel, orally available,targeted therapies for cancer., Pursuant ... to several,small molecules for the treatment of cancer, ...
... Paper Provides Rationale for Continued Development of CNDO103 as ... ... Coronado Biosciences Inc. today,announced the publication of data demonstrating that the ... while,demonstrating less toxicity than Gossypol in vivo in mice., Published ...
... Jan. 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), ... wave of,antibody therapeutics, today announced it has completed ... to discuss the upcoming IND,submission for ARH460-16-2, its ... anti-cancer antibody targeting a novel epitope of CD44,found ...
Cached Biology Technology:Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 2Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 3
(Date:4/17/2014)... hydrogen sulfide in order to properly multiply and form ... Center for Craniofacial Molecular Biology at the Herman Ostrow ... principal investigator on the project, said the presence of ... of calcium ions. The essential ions activate a chain ... creation of new bone tissue, and keeps the breakdown ...
(Date:4/17/2014)... in German . ... money demanded of him, he can expect his premises to ... fear of the consequences is enough to make restaurant owners ... which lay their eggs in other birds, nests. If the ... take their revenge by destroying the entire nest. Consequently, it ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
Breaking Biology News(10 mins):Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... "dietary fibre". But what is dietary fibre and how do ... Structural Biology Laboratory, in collaboration with groups in Canada, the ... bacteria metabolise the complex dietary carbohydrates found in fruits and ... are about ten times more bacterial cells in the average ...
... alien world of aquatic micro-organisms just got new residents: ... has developed a class of tiny bio-hybrid machines that ... traverse the viscous fluids of biological environments on their ... Gutgsell Professor of mechanical science and engineering, the team ...
... researchers from the University of Nebraska-Lincoln, while using a ... Ice Shelf, unexpectedly discovered a new species of small ... tentacles protruding into frigid water like flowers from a ... it was really an amazing find," said Marymegan Daly, ...
Cached Biology News:York scientists investigate the fiber of our being 2Tiny swimming bio-bots boldly go where no bot has swum before 2New sea anemone species discovered in Antarctica 2New sea anemone species discovered in Antarctica 3New sea anemone species discovered in Antarctica 4
... ejector is a unique product that facilitates ... their holder. Linkage: This CLS number is ... match Cornings product number. If showing no ... Sigma-Aldrich number (Z71,314-7) or contact customer service ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
... modular cleanroom for biological safety labs ... cleanliness (to Class 10/ISO 3) and ... create ultra-smooth surfaces that are easy ... radius corners simplify cleaning. Unique double-wall ...
... The Staccato Series of systems provide ... drug discovery , genomics, proteomics and drug ... three base configurations; Mini Workstation Series, Application ... Sciclone ELISA Station is a remarkably compact ...
Biology Products: